130 related articles for article (PubMed ID: 36999533)
1. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Yoo C; Javle MM; Verdaguer Mata H; de Braud F; Trojan J; Raoul JL; Kim JW; Ueno M; Lee CK; Hijioka S; Cubillo A; Furuse J; Azad N; Sato M; Vugmeyster Y; Machl A; Bajars M; Bridgewater J; Oh DY; Borad MJ
Hepatology; 2023 Sep; 78(3):758-770. PubMed ID: 36999533
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
[TBL] [Abstract][Full Text] [Related]
3. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Cho BC; Lee JS; Wu YL; Cicin I; Dols MC; Ahn MJ; Cuppens K; Veillon R; Nadal E; Dias JM; Martin C; Reck M; Garon EB; Felip E; Paz-Ares L; Mornex F; Vokes EE; Adjei AA; Robinson C; Sato M; Vugmeyster Y; Machl A; Audhuy F; Chaudhary S; Barlesi F
J Thorac Oncol; 2023 Dec; 18(12):1731-1742. PubMed ID: 37597750
[TBL] [Abstract][Full Text] [Related]
4. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
Oaknin A; Ghamande SA; Kasamatsu Y; Gil-Martin M; Grau-Bejar JF; Garcia-Duran C; Sato M; Siddiqui A; Chaudhary SP; Vugmeyster Y; Hasegawa K
Clin Cancer Res; 2024 Mar; 30(5):975-983. PubMed ID: 38165683
[TBL] [Abstract][Full Text] [Related]
6. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Doi T; Fujiwara Y; Koyama T; Ikeda M; Helwig C; Watanabe M; Vugmeyster Y; Kudo M
Oncologist; 2020 Sep; 25(9):e1292-e1302. PubMed ID: 32324927
[TBL] [Abstract][Full Text] [Related]
8. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
[TBL] [Abstract][Full Text] [Related]
9. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Khasraw M; Weller M; Lorente D; Kolibaba K; Lee CK; Gedye C; I de La Fuente M; Vicente D; Reardon DA; Gan HK; Scott AM; Dussault I; Helwig C; Ojalvo LS; Gourmelon C; Groves M
Neurooncol Adv; 2021; 3(1):vdab058. PubMed ID: 34056607
[TBL] [Abstract][Full Text] [Related]
10. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Tan B; Khattak A; Felip E; Kelly K; Rich P; Wang D; Helwig C; Dussault I; Ojalvo LS; Isambert N
Target Oncol; 2021 Jul; 16(4):435-446. PubMed ID: 34009501
[TBL] [Abstract][Full Text] [Related]
11. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
Paz-Ares L; Kim TM; Vicente D; Felip E; Lee DH; Lee KH; Lin CC; Flor MJ; Di Nicola M; Alvarez RM; Dussault I; Helwig C; Ojalvo LS; Gulley JL; Cho BC
J Thorac Oncol; 2020 Jul; 15(7):1210-1222. PubMed ID: 32173464
[TBL] [Abstract][Full Text] [Related]
12. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Valle JW; Vogel A; Denlinger CS; He AR; Bai LY; Orlova R; Van Cutsem E; Adeva J; Chen LT; Obermannova R; Ettrich TJ; Chen JS; Wasan H; Girvan AC; Zhang W; Liu J; Tang C; Ebert PJ; Aggarwal A; McNeely SC; Moser BA; Oliveira JM; Carlesi R; Walgren RA; Oh DY
Lancet Oncol; 2021 Oct; 22(10):1468-1482. PubMed ID: 34592180
[TBL] [Abstract][Full Text] [Related]
13. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Javle M; Borad MJ; Azad NS; Kurzrock R; Abou-Alfa GK; George B; Hainsworth J; Meric-Bernstam F; Swanton C; Sweeney CJ; Friedman CF; Bose R; Spigel DR; Wang Y; Levy J; Schulze K; Cuchelkar V; Patel A; Burris H
Lancet Oncol; 2021 Sep; 22(9):1290-1300. PubMed ID: 34339623
[TBL] [Abstract][Full Text] [Related]
14. Identification of
Spira A; Awada A; Isambert N; Lorente D; Penel N; Zhang Y; Ojalvo LS; Hicking C; Rolfe PA; Ihling C; Dussault I; Locke G; Borel C
Front Oncol; 2022; 12():981940. PubMed ID: 36568239
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
16. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
[TBL] [Abstract][Full Text] [Related]
17. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
[TBL] [Abstract][Full Text] [Related]
18. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
20. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ; Fan J; Oh DY; Choi HJ; Kim JW; Chang HM; Bao L; Sun HC; Macarulla T; Xie F; Metges JP; Ying J; Bridgewater J; Lee MA; Tejani MA; Chen EY; Kim DU; Wasan H; Ducreux M; Bao Y; Boyken L; Ma J; Garfin P; Pant S;
Lancet Oncol; 2023 Jul; 24(7):772-782. PubMed ID: 37276871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
